Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population‐Based , Prospective Study and Mendelian Randomization Analysis
Arthritis & Rheumatology · 2023-09 · 75 (9) · 1648-1657
DOI: 10.1002/art.42523 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 12.07.2023. Verfasst von Amit D Joshi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Uric Acid, Gout. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, BLRD VA, National Institutes of Health.
Abstract (Originalsprache)
Objective
To prospectively investigate population‐based metabolomics for incident gout and reproduce the findings for recurrent flares, accounting for serum urate.
Methods
We conducted a prediagnostic metabolome‐wide analysis among 105,615 UK Biobank participants with nuclear magnetic resonance metabolomic profiling data (168 total metabolites) from baseline blood samples collected 2006–2010 in those without history of gout. We calculated hazard ratios (HRs) for incident gout, adjusted for gout risk factors, excluding and including serum urate levels, overall and according to fasting duration before sample collection. Potential causal effects were tested with 2‐sample Mendelian randomization. Poisson regression was used to calculate rate ratios (RRs) for the association with recurrent flares among incident gout cases.
Results
Correcting for multiple testing, 88 metabolites were associated with risk of incident gout (N = 1,303 cases) before serum urate adjustment, including glutamine and glycine (inversely), and lipids, branched‐chain amino acids, and most prominently, glycoprotein acetyls (GlycA; P = 9.17 × 10 −32 ). Only GlycA remained associated with incident gout following urate adjustment (HR 1.52 [95% confidence interval (95% CI) 1.22–1.88] between extreme quintiles); the HR increased progressively with fasting duration before sample collection, reaching 4.01 (95% CI 1.36–11.82) for ≥8 hours of fasting. Corresponding HRs per SD change in GlycA levels were 1.10 (95% CI 1.04–1.17) overall and 1.54 (95% CI 1.21–1.96) for ≥8 hours of fasting. GlycA levels were also associated with recurrent gout flares among incident gout cases (RR 1.90 [95% CI 1.27–2.85] between extreme quintiles) with larger associations with fasting. Mendelian randomization corroborated a potential causal role for GlycA on gout risk.
Conclusion
This prospective, population‐based study implicates GlycA, a stable long‐term biomarker reflecting neutrophil overactivity, in incident and recurrent gout flares (central manifestation from neutrophilic synovitis) beyond serum urate. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston.
- Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, and The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, and Department of Medicine, Harvard Medical Sch…
- Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston.
- Department of Medicine, University of Mississippi Medical Center, Jackson.
- San Diego VA Healthcare Service and University of California San Diego, La Jolla, California.
- Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, and Department of Biochemistry, University of Otago, Dunedin, New Zealand.
ORCID-Profile: Natalie McCormick, Chio Yokose, Adrienne Tin, Tony R Merriman, Hyon K Choi
Förderung
- NIAMS NIH HHS
- BLRD VA
- National Institutes of Health
Zitieren
APA
Joshi, A. D., McCormick, N., Yokose, C., Yu, B., Tin, A., Terkeltaub, R., Merriman, T. R., Eliassen, A. H., Curhan, G. C., Raffield, L. M., & Choi, H. K. (2023). Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population‐Based , Prospective Study and Mendelian Randomization Analysis. Arthritis & Rheumatology, 75(9), 1648-1657. https://doi.org/10.1002/art.42523
Vancouver
Joshi AD, McCormick N, Yokose C, Yu B, Tin A, Terkeltaub R, et al. Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population‐Based , Prospective Study and Mendelian Randomization Analysis. Arthritis & Rheumatology. 2023;75(9):1648-1657. doi:10.1002/art.42523
BibTeX
@article{Joshi2023,
author = {Joshi, Amit D and McCormick, Natalie and Yokose, Chio and Yu, Bing and Tin, Adrienne and Terkeltaub, Robert and Merriman, Tony R and Eliassen, A Heather and Curhan, Gary C and Raffield, Laura M and Choi, Hyon K},
title = {Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population‐Based , Prospective Study and Mendelian Randomization Analysis},
journal = {Arthritis & Rheumatology},
year = {2023},
volume = {75},
number = {9},
pages = {1648--1657},
doi = {10.1002/art.42523}
}
EUVIMED